BR0014071A - Formulações para uso parenteral de fosfato de estramustina e aminoácidos - Google Patents

Formulações para uso parenteral de fosfato de estramustina e aminoácidos

Info

Publication number
BR0014071A
BR0014071A BR0014071-6A BR0014071A BR0014071A BR 0014071 A BR0014071 A BR 0014071A BR 0014071 A BR0014071 A BR 0014071A BR 0014071 A BR0014071 A BR 0014071A
Authority
BR
Brazil
Prior art keywords
formulations
parenteral use
amino acids
estramustine phosphate
phosphate
Prior art date
Application number
BR0014071-6A
Other languages
English (en)
Inventor
Lorena Muggetti
Paolo Colombo
Alessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0014071A publication Critical patent/BR0014071A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULAçõES PARA USO PARENTERAL DE FOSFATO DE ESTRAMUSTINA E AMINOáCIDOS Uma formulação farmacêutica que compreende um carreador ou diluente aceitável parenteralmente, fosfato de estramustina e um aminoácido básico. A formulação pode ser administrada de acordo com um regime de quimioterapia combinada em associação com um ou mais agentes quimioterapêuticos. A formulação também possibilita a administração de fosfato de estramustina sem efeitos colaterais no local da injeção.
BR0014071-6A 1999-09-16 2000-09-13 Formulações para uso parenteral de fosfato de estramustina e aminoácidos BR0014071A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921960.2A GB9921960D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate and amino acids
PCT/EP2000/008983 WO2001019372A1 (en) 1999-09-16 2000-09-13 Formulations for parenteral use of estramustine phosphate and amino acids

Publications (1)

Publication Number Publication Date
BR0014071A true BR0014071A (pt) 2002-05-21

Family

ID=10861070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014071-6A BR0014071A (pt) 1999-09-16 2000-09-13 Formulações para uso parenteral de fosfato de estramustina e aminoácidos

Country Status (22)

Country Link
EP (1) EP1214078B1 (pt)
JP (1) JP2003509372A (pt)
KR (1) KR20020059592A (pt)
CN (1) CN1373667A (pt)
AT (1) ATE283053T1 (pt)
AU (1) AU779922B2 (pt)
BR (1) BR0014071A (pt)
CA (1) CA2384726A1 (pt)
CZ (1) CZ2002945A3 (pt)
DE (1) DE60016252D1 (pt)
EA (1) EA005311B1 (pt)
GB (1) GB9921960D0 (pt)
HK (1) HK1048948A1 (pt)
HU (1) HUP0202729A3 (pt)
IL (1) IL148513A0 (pt)
MX (1) MXPA02002854A (pt)
NO (1) NO20021302L (pt)
NZ (1) NZ518182A (pt)
PL (1) PL354746A1 (pt)
SK (1) SK3442002A3 (pt)
WO (1) WO2001019372A1 (pt)
ZA (1) ZA200202689B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318689B1 (it) * 2000-09-12 2003-08-27 Pharmacia & Upjohn Spa Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
ES2557475T3 (es) 2005-06-17 2016-01-26 Vital Health Sciences Pty Ltd. Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents
GB2471065A (en) * 2009-06-10 2010-12-22 Univ Sheffield Modulator of claspin for treatment of cell proliferative disorder
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd AMINO-QUINOLINES AS KINASE INHIBITORS
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
US10736845B2 (en) 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
CN110662733A (zh) 2016-12-21 2020-01-07 埃维科生物技术有限公司 方法
WO2024102547A1 (en) * 2022-11-11 2024-05-16 Michael Farber Anhydrous compositions of polysorbates and cyclodextrins for shelf stable drug combinations with macrocyclic lactone complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807572A (en) * 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents

Also Published As

Publication number Publication date
EA200200368A1 (ru) 2002-10-31
NO20021302L (no) 2002-04-24
EP1214078A1 (en) 2002-06-19
KR20020059592A (ko) 2002-07-13
ZA200202689B (en) 2003-10-29
HUP0202729A2 (hu) 2003-01-28
AU7776200A (en) 2001-04-17
EP1214078B1 (en) 2004-11-24
ATE283053T1 (de) 2004-12-15
PL354746A1 (en) 2004-02-23
MXPA02002854A (es) 2003-07-21
CA2384726A1 (en) 2001-03-22
HK1048948A1 (zh) 2003-04-25
SK3442002A3 (en) 2002-09-10
CZ2002945A3 (cs) 2002-07-17
DE60016252D1 (de) 2004-12-30
WO2001019372A1 (en) 2001-03-22
CN1373667A (zh) 2002-10-09
HUP0202729A3 (en) 2003-12-29
NO20021302D0 (no) 2002-03-15
AU779922B2 (en) 2005-02-17
IL148513A0 (en) 2002-09-12
JP2003509372A (ja) 2003-03-11
GB9921960D0 (en) 1999-11-17
EA005311B1 (ru) 2004-12-30
NZ518182A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
BR0014071A (pt) Formulações para uso parenteral de fosfato de estramustina e aminoácidos
TR200002299T2 (tr) Epotilon kompozisyonları.
BR0313575C1 (pt) Método para melhorar a eficácia e/ou transporte transdermal de nutrientes e nutricêuticos topicamente administrados, veìculo para ser utilizado da administração tópica ou transdermal de nutrientes ou nutricêuticos, composição nutricêutica e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons junto com outros excipientes
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
BR0106681A (pt) Fórmula pediátrica e métodos para prover nutrição a pacientes pediátricos e para melhorar tolerância em pacientes pediátricos
AP2004003120A0 (en) Combined use of antitumor indolopyrrolocarbazole derivatives and other antitumor agent
CA2417800A1 (en) Novel microemulsion and micelle systems for solubilizing drugs
BRPI0513673A (pt) método para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, veìculo utilizado na administração enteral de compostos biologicamente ativos, composição farmacêutica e uso de uma quantidade eficaz de um ou mais derivados de fosfato
IL140930A0 (en) Compounds and compositions for delivering active agents
EP1093819A3 (en) Compounds and compositions for delivering active agents
TR200003108T2 (tr) İlaç kompozisyonları
ES2051678T1 (es) Derivados de 5-oxo-l-prolina y uso farmaceutico de los mismos.
SV2002000137A (es) Productos farmaceuticos beta-carbolina ref n. 29342/36539 el
NZ501235A (en) Topical compositions containing emulsion of a discontinuous phase which is an eutectic mixture of two pharmaceutical agents and a continuous phase
MX9801727A (es) Composicion farmaceutica para administracion oral.
BR0008468A (pt) Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos
ATE378070T1 (de) Zusammensetzung mit fulvestrant
BR0014062A (pt) Formulações para uso parenteral de fosfato de estramustina e sulfoalquileter ciclodextrinas
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
BR0014063A (pt) Formulações papa uso parenteral de fosfato de estramustina com propriedades farmacológicas melhoradas
NO20020631L (no) Formuleringer for parenteral bruk av estramustinfosfat og albumin
NO950950L (no) Farmasöytisk preparat
NZ501987A (en) Single, high dosage intravenous administration of estramustine phosphate
AU2001289762A1 (en) Pharmaceutical extemporary compositions
BR9814090A (pt) Composição de drogas rapidamente solúvel

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.